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Background: Epithelial cell adhesion molecule is overexpressed in bladder tumours and released from bladder cancer cells in vitro.
We test the hypotheses that urinary EpCAM could act as a biomarker for primary bladder cancer detection and risk stratification.
Methods: Epithelial cell adhesion molecule was measured by ELISA in urine from 607 patients with primary bladder tumours and
in urine from 53 non-cancer controls. Mann–Whitney tests and ROC analyses were used to determine statistical significance and
discrimination between non-cancer controls and different stages and grades of disease. Multivariable modelling and Kaplan–
Meier analyses were used to determine prognostic significance. The structure of urinary EpCAM was investigated by western
blotting and mass spectrometry.
Results: Urinary EpCAM levels increase with stage and grade of bladder cancer. Alongside grade and stage, elevated urinary
EpCAM is an independent indicator of poor prognosis with a hazard ratio of 1.76 for bladder cancer-specific mortality. The soluble
form of EpCAM in urine is the extracellular domain generated by cleavage between ala243 and gly244. Further studies are
required to define the influence of other urinary tract malignancies and benign urological conditions on urinary EpCAM.
Conclusion: The extracellular domain of EpCAM is shed into urine by bladder tumours. Urinary EpCAM is a strong indicator of
bladder cancer-specific survival, and may be useful within a multi-marker panel for disease detection or as a stand-alone marker to
prioritise the investigation and treatment of patients. The mechanisms and effects of EpCAM cleavage in bladder cancer are
worthy of further investigation, and may identify novel therapeutic targets.
Urothelial bladder cancer (UBC) is the fifth most common cancer
in Western societies accounting for 38 200 and 17 000 deaths per
year in the EU and USA, respectively, and with a rising global
incidence (Ploeg et al, 2009; Burger et al, 2013). The majority of
patients present with painless visible haematuria, and at presenta-
tion over 75% of UBCs detected by cystoscopy are non-muscle-
invasive tumours (NMIBC: stages Ta/T1/Tcis; Burger et al, 2013).
For these patients, long-term cystoscopic surveillance is required
following an initial endoscopic tumour resection (Babjuk et al,
2011). Such surveillance is invasive, uncomfortable, time consuming
and expensive (Mowatt et al, 2010). Muscle-invasive disease
(MIBC: stages T2þ ) requires more radical treatment and carries
a 5-year survival rate of only 27–50% (Stenzl et al, 2011).
Consequently, an important goal in UBC research is the
development of non-invasive tests to reduce reliance upon
cystoscopy for detection and surveillance. Commercially available
urinary biomarkers are either soluble urinary proteins (e.g.,
NMP22, BTA) or based on the detection of tumour cells in urine
(ImmunoCyt, UroVysion; reviewed in Tilki et al (2011)). Some of
the protein-based tests have higher sensitivity for early disease than
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cytology, but lower specificity (Hennenlotter et al, 2011; Miyake
et al, 2012a, b). Recently, nucleic acid markers (e.g., DNA
methylation, mutations, microRNAs) have shown promise for
UBC detection (Reinert et al, 2011; Miah et al, 2012; Allory et al,
2013; Zuiverloon et al, 2013).
In addition, whereas clinical and pathological factors enable risk
stratification, molecular markers could potentially provide addi-
tional prognostic information to further inform management
where decision-making can be difficult, such as in the treatment of
highest risk NMIBC (Babjuk et al, 2011), or the utilisation of
bladder-preserving strategies for MIBC (James et al, 2012). To our
knowledge no individual urinary protein biomarker has shown an
independent prognostic value, although urine protein-based tests
are desirable due to the ease of measurement and the potential for
point of care testing.
We recently published an analysis of the proteins secreted by
UBC cell lines (Shimwell et al, 2013), and now report a large-scale
evaluation of one of these proteins, EpCAM, as a urinary
biomarker for the detection and risk stratification of UBC. As
EpCAM is an integral membrane protein and not expected to be
present in urine, we also investigated whether EpCAM is released
intact or by shedding of the extracellular domain.
PATIENTS AND METHODS
Patient samples. Urine samples were prospectively collected for
biomarker research between 2006 and 2009 as part of the Bladder
Cancer Prognosis Programme (ethics approval 06/MRE04/65;
Zeegers et al, 2010). Patients were enrolled into the study on the
basis of initial cystoscopic findings suggestive of primary UBC. All
patients were newly diagnosed with UBC, and had not received
treatment for UBC prior to urine collection. Subsequently, all
patients were treated according to current standard practice.
Inclusion and exclusion criteria are described in detail elsewhere
(Zeegers et al, 2010). Mid-stream urine was collected prior to
endoscopic tumour resection (TURBT). Samples were placed on
ice, centrifuged at 2000 r.p.m. for 10min within 8 h of collection
and the supernatants stored at  80 1C. As patient recruitment
occurred prior to histopathological confirmation of UBC, a
proportion of patients were ultimately diagnosed with non-
malignant conditions and these serve as the non-cancer ‘controls’.
Patient information is shown in Table 1.
ELISAs. Urine samples were vortexed at room temperature and
centrifuged at 15 000 g for 5min prior to use. The EpCAM ELISA
utilises capture and detection antibodies raised against the
extracellular domain of recombinant human EpCAM (DY960;
R&D Systems Europe Ltd, Abingdon, UK). To each well of the
assay were added 100 ml of urine and 50 ml of PBSþ 1% BSA, and
seven-point calibration curves constructed using two-fold dilutions
of 1 ngml 1 standard.
Data analysis. EpCAM levels are presented as medians and
statistical significance was calculated using Mann–Whitney tests.
Bladder cancer-specific survival was defined as the time from
registration into the BCPP study to date of death from bladder
cancer. Patients were censored at the date last known to be alive or
date of non-bladder cancer-related death. Univariable Cox
proportional hazards models were employed (alpha 0.1) to identify
factors to be included in a multivariable model; significance was set
at 0.05. Analysis was done in Stata 12.1 (StataCorp, College Station,
TX, USA).
Western blotting. Samples were boiled in SDS-PAGE sample
loading buffer containing 50mM DTT, separated with 4–12%
NuPAGE gels, blotted onto PVDF and probed with biotinylated
anti-EpCAM antibody (BAF960; R&D Systems Europe Ltd) and
streptavidin-linked HRP. Selected samples were deglycosylated by
incubating at 37 1C for 2 h with 100 units per ml PNGase F (F8435;
Sigma-Aldrich Company Ltd., Dorset, UK) in 150mM NaCl, 50mM
Tris (pH 7.4), 1% Triton X-100 and 50mM DTT.
Affinity purification and mass spectrometry. Ten ml of urine
was incubated with 5 mg of biotinlyated anti-EpCAM antibody and
100 ml of strepdavidin-coated beads at 4 1C overnight. The beads
were washed with 150mM NaCl, 50mM Tris (pH 7.4), 0.05%
Tween 20 and proteins eluted by boiling in SDS-PAGE sample
loading buffer. Following SDS-PAGE, gel slices were destained,
reduced with 50mM DTT, alkylated with 100mM iodoacetamide
and digested overnight with 250 ng of sequencing grade trypsin or
asp-N (Promega UK, Southampton, Hampshire, UK). Mass
spectrometry details are provided in Supplementary Information.
RESULTS
Urinary EpCAM levels in UBC. Compared to non-cancer
controls, EpCAM was significantly elevated in patients with UBC
(median 6.74 pg per mg creatinine vs 3.86, P¼ 0.0025); however,
the area under the ROC curve was only 0.625 and it was evident
that elevation was confined to late stage and high-grade disease
(Figures 1A–C). Stratifying by stage revealed significant elevation
in T1 and T2þ , but not Ta UBCs (P-values o0.0001, o0.0001
and 0.96, respectively). Stratifying by grade revealed no EpCAM
elevation in G1 or G2 UBCs (P40.05), but significant elevation in
G3 UBCs compared to both control subjects and patients with G1
or G2 UBCs (Po0.0001).
Urinary EpCAM as a diagnostic marker. Using a threshold of
24 pg EpCAM per mg creatinine (mean±2 s.d. in the 53 control
subjects), 5%, 20% and 38% of Ta, T1 and T2þ UBCs and 2%, 7%
and 30% of G1, G2 and G3 UBCs, respectively, gave a positive test
result with a false-positive rate of 6% in the controls. Thus, elevated
urinary levels of EpCAM are highly indicative of the presence of
T2þ or G3 UBC. The area under the ROC curve for detecting
T2þ UBC was 0.805 (0.742–0.858, 95% CI), 0.765 for G3 UBC
Table 1. Patient information
Stage n Male/female Grade (1/2/3) Age (years) Creatinine (lgml1) EpCAM (pgml1) EpCAM (pgmg1 creatinine)
Control 53 33/9 — 70 (63–70) 1488 (953–2212) 6.4 (3.3–12.2) 3.86 (1.22–4.91)
Ta 297 228/69 129/129/39 73 (64–80) 1674 (1018–2388) 6.4 (1.7–13.5) 3.93 (1.02–8.15)
T1 169 147/22 3/46/120 75 (66–81) 1722 (1167–2115) 13.0 (6.0–32.8) 9.29 (3.73–21.10)
T2þ 141 108/33 0/6/135 78 (68–83) 1452 (989–2111) 23.1 (10.4–47.5) 16.00 (7.70–35.2)
Abbreviations: EpCAM¼Epithelial cell adhesion molecule; UBC¼Urothelial bladder cancer The table shows the number of patients in each group and numbers of males, females and each
grade of UBC. All other values are presented as medians (lower quartile–upper quartile). Of the control subjects, 13 had no urinary tract abnormality detectable, 24 had cystitis and 16 had other
non-malignant conditions.
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(0.716–0.809) and 0.725 for G3 NMIBC (0.659–0.784) (Figure 2A–C).
At a specificity of 90% (79.3–96.8), the sensitivity for detecting
MIBC was 59.6% (51.0–67.7), increasing to 72.3% (64.2–79.5) at
80% (68.0–90.5) specificity.
Urinary EpCAM as a prognostic marker. Univariable analyses
included age (years), multiple tumours (1 vs 2þ ), grade (1, 2 vs 3),
size of largest tumour (p3 cm vs43 cm), CIS (present vs absent),
stage (Ta or T1 vs T2þ ), sex (male vs female) and urinary
EpCAM (normal vs elevated). Grade, stage, age, tumour size, CIS
and EpCAM were statistically significant (Po0.005). Multivariable
analysis showed that elevated urinary EpCAM (424 pg EpCAM
per mg creatinine) was an independent prognostic factor with a
hazard ratio of 1.8 (95% CI 1.1, 2.7: P¼ 0.012) for UBC-specific
survival (Table 2 and Figure 3).
Urinary EpCAM characterisation. To determine whether urinary
EpCAM is the intact membrane-bound protein or a soluble
fragment, we measured EpCAM in six samples pre- and post-
ultracentrifugation (140 000 g, 30min): there was no difference in
urinary EpCAM concentration, indicating that urinary EpCAM is
not membrane bound. We then investigated EpCAM by western
blotting, initially analysing UBC cell lines to determine the
mobility of full-length EpCAM— this migrated as a single band
at 48 kDa (Figure 4A). Urine from six UBC patients (4300 pg per
ml 1 EpCAM) showed three bands with molecular weights of 42,
35 and 27 kDa, which varied in intensity between the patients
(Figure 4B). Deglycosylation decreased the intensities of the higher
molecular weight bands and increased those of the lower molecular
weight bands (Figure 4C), indicating that the multiple bands are
different glycoforms rather than different fragments of EpCAM.
The molecular weight of the lowest band closely matched that
calculated for the extracellular region of EpCAM (27.4 kDa). Mass
spectrometry of tryptic digests of affinity purified urinary EpCAM
identified peptides covering most of the extracellular domain and
none from the transmembrane or intracellular domains (Figure 5
and Supplementary Information). The data revealed that the
cleavage site resulting in shedding of the extracellular domain was
either between lys242 and ala243 or between ala243 and gly244,
immediately adjacent to the predicted transmembrane span. Using
asp-N (instead of trypsin) we identified two further peptides
(DEKAPEFSMQGLKA and DEKAPEFSMQGLK), unequivocally
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Figure 1. Urinary EpCAM in UBC by stage (A), grade in all UBC (B) and grade in NMIBC (C). Data are shown for individual patients expressed as
pg EpCAM per mg creatinine.
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Figure 2. Detection of UBC using urinary EpCAM. The ROC curves show discrimination between stages of UBC and non-cancer controls (A)
grades of UBC and non-cancer controls (B) and grades of NMIBC and non-cancer controls (C). Panel A: dotted line¼Ta, dashed line¼T1, solid
line¼T2þ . Panels B and C: dotted line¼grade 1, dashed line¼grade 2, solid line¼grade 3.
Table 2. Multivariable analysis of prognostic indicators
Variable b s.e. (b) HR P-value HR 90% CI
Grade (Reference Category: p2)
Grade 3 1.135 0.422 3.111 0.007 1.361 7.108
Stage (Reference Category: Ta or T1)
T2 þ 2.205 0.295 9.070 o0.001 5.090 16.165
EpCAM (Reference Category: o24 pg per mg creatinine)
424pg/mg 0.567 0.226 1.763 0.012 1.132 2.746
Abbreviations: EpCAM¼Epithelial cell adhesion molecule; HR¼Hazard ratio.
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demonstrating that the cleavage site is ala243/gly244 with
additional, possibly secondary, cleavage occurring at lys242/ala243.
Urinary EpCAM stability. We incubated eight urine samples at
25 1C for up to 1 week. Four of these samples had high natural
levels of EpCAM (4300 pgml 1) and 490% of the EpCAM
remained after 3 days (Figure 6). To test whether low levels of
EpCAM in some urine samples might be due to faster degradation,
we selected four samples with low levels of EpCAM (o50 pgml 1)
and added 200ngml 1 recombinant human EpCAM (the standard
for the ELISA); in these samples degradation was slightly faster, with
levels decreasing to 60% after 3 days.
Urinary EpCAM and haematuria. Haematuria did not signifi-
cantly influence urinary EpCAM in the non-UBC or T2þ patient
groups, although an association between haematuria and EpCAM
was observed in NMIBCs (Table 3). However, there was no direct
association between haematuria and urinary EpCAM; a strong
correlation between urinary EpCAM and albumin concentration
would be expected if blood or plasma leakage was responsible for
elevating urinary EpCAM, but this was not the case
(Supplementary Data).
DISCUSSION
Elevated urinary EpCAM is observed in many patients with grade
three and stage T2þ UBCs, and is a significant independent
prognostic factor for UBC-specific survival. The predominant form
of EpCAM in urine is not the intact protein, but a soluble and
stable form comprised of the entire extracellular domain.
Urinary EpCAM appears to be specific to high-grade and stage
UBC, as elevated levels were seen in only 2% of patients with grade100
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one UBC, 7% with grade two but 30% with grade three, and only
5% of patients with Ta, 20% with T1 but 38% with T2þ UBC.
Moreover, elevated urinary EpCAM increases the risk of UBC-
specific death 1.8-fold. Thus, although sensitivity as a diagnostic
marker for UBC is poor (and a role in surveillance unlikely),
urinary EpCAM may have a role in rapidly detecting those patients
with the most advanced and/or aggressive disease so that their
investigation and management can be tailored and expedited
accordingly. Although other urinary protein markers are also
elevated in advanced UBC, their value as independent prognostic
factors has not been demonstrated.
EpCAM is a type-1 cell surface protein comprised of 291
residues with the N-terminal 242 residues being extracellular, 23
residues predicted to form a transmembrane helix and the
C-terminal 26 residues being located intracellularly (Szala et al,
1990). The extracellular part of the protein is glycosylated at
asparagines 51, 88 and 175, and the region spanning residues
4—112 is stabilised by six intramolecular disulphide bonds (Chong
and Speicher, 2001). The latter region has sequence similarity with
the EGF and thyrobulin type-1 domain, whereas the C-terminal
half of the extracellular region is unique and remains unchar-
acterised (Chong and Speicher, 2001).
EpCAM is overexpressed in many epithelial malignancies,
including bladder CIS (Patriarca et al, 2009), and high-grade and
advanced stage UBCs (Brunner et al, 2008). The tumour-specific
expression of EpCAM has led to its use for capturing circulating
UBC cells (Okegawa et al, 2010), and also as a target for directing
therapies to bladder tumours (Kowalski et al, 2010). Serum levels
of EpCAM have been measured previously – they are typically in
the low ngml 1 range (Abe et al, 2002; Petsch et al, 2011) and are
slightly elevated in patients with oesophageal cancers (Kimura et al,
2007). Epithelial cell adhesion molecule expression is a prognostic
indicator in several cancers; in UBC, Brunner et al (2008) reported
that high tissue levels of EpCAM are associated with poor
prognosis. Their study investigated 99 patients with various stages
of UBC and looked at overall survival: multivariate analysis
highlighted age, stage and number of recurrences, but not EpCAM
expression, as independent factors. Urinary EpCAM concentration
is likely to be dependent not only on tissue expression levels, but
also on the rate of shedding into the urine. Our analysis of over 600
patients indicates that urinary EpCAM is a prognostic factor for
UBC-specific survival, independent of grade and stage.
Despite its long association with cancer, the role of EpCAM has
remained elusive with both tumour suppressor and oncogenic
properties reported. Maetzel et al (2009) demonstrated that
EpCAM can be sequentially cleaved to release its extracellular
and intracellular domains, ‘EpEX’ and ‘EpICD’, respectively;
EpICD diffuses into the nucleus and activates oncogenic signalling
events (Maetzel et al, 2009; Chaves-Pe´rez et al, 2013). Our data
indicate that these phenomena also occur in UBC, with urinary
‘EpEX’ associated with high-grade and stage UBCs with poor
prognosis. In support of this, Ralhan et al (2010) recently
performed immunohistochemistry for EpICD in a range of human
epithelial cancers, including 10 cases of UBC, nine of which were
positive for EpICD. In UBC we have shown that the extracellular
domain of EpCAM is released by cleavage immediately adjacent to
the cell membrane. The precise location of the cleavage that
released EpEX was not described by Maetzel et al (2009), but the
protease involved (TACE or ADAM 17) usually cleaves membrane
proteins 10–15 residues away from the membrane surface
(Coglievina et al, 2013), suggesting atypical cleavage or an
alternative mechanism of extracellular domain release in UBC.
It is probable that a diagnostic test for UBC will require multiple
markers to reach the high sensitivity and specificity required in the
clinic. Elevated urinary EpCAM levels are highly indicative of
MIBC, thus representing a candidate that could be incorporated
into a test to stratify patients at presentation into those at low or
high risk of harbouring MIBC, and subsequently tailoring their
investigation and management (Shimwell et al, 2013). For example,
staging CT or MRI for MIBC is typically performed after TURBT
which can cause artefact, hindering local staging, misinforming
clinical decisions and delaying definitive treatment. Urinary
biomarkers could be used to expedite CT or MRI before TURBT,
thus improving diagnosis and local staging, and potentially
reducing delays. However, the main clinical benefit of urinary
EpCAM may be its independent prognostic value, thus informing
clinical decisions in a number of settings, such as in the treatment
Table 3. (a) Urinary EpCAM stratified according to haematuria and disease stage and (b) number of patients in each category
Haematuria Non-UBC Ta T1 T2þ
(a) Urinary EpCAM (pgmg1)
 3.96 (1.64–7.33) 3.44 (0.82–7.52) 6.25 (1.33–12.2) 16.2a (6.08–29.4)
þ 3.88 (2.34–9.42) 5.59b (2.55–12.03) 10.9a,b (5.01–30.4) 16.9a (7.92–41.6)
(b) Number of patients
 41 205 64 31
þ 12 92 105 110
Abbreviation: UBC¼ Urothelial bladder cancer
aIndicates Po0.05 relative to all non-UBC.
bIndicates a Po0.05 difference between haematuria negative and positive for that disease stage.
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Figure 6. EpCAM stability in urine. Urine samples were incubated for
up to 1 week at 25 1C and EpCAM levels measured by ELISA. The data
shown are the mean (s.e.m.) values from four urine samples with high
levels of EpCAM (476–931pgml 1; open symbols) and four urine
samples with low levels of EpCAM augmented with 200pgml 1
recombinant EpCAM.
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of highest risk NMIBC (Babjuk et al, 2011), or the utilisation of
bladder-preserving strategies for MIBC (James et al, 2012).
A major strength of our approach is the prospective nature of
the biospecimen collection, specifically undertaken to carry out
such biomarker research (Zeegers et al, 2010). However, further
studies in an independent cohort will be needed to validate our
findings; such a cohort should include more non-UBC samples to
thoroughly define the effects of benign bladder conditions and
other urological malignancies on urinary EpCAM, and this work is
ongoing. Although beyond the scope of this initial urinary EpCAM
description and characterisation, future work should also investi-
gate whether urinary EpCAM is a prognostic biomarker in
recurrent as well as primary UBCs and whether it is predictive
of therapeutic responses.
CONCLUSIONS
Urinary EpCAM may prove useful for facile identification of
patients with high-risk poor-prognosis UBC. The overexpression
of EpCAM in UBC (Brunner et al, 2008), its detection in
conditioned media from the UBC cell lines (Shimwell et al, 2013)
and the data presented here indicate that the source of
the EpCAM extracellular domain in the urine of UBC patients
is shedding directly from tumour cells. Further investigation
of EpEX and EpICD in MIBC may reveal novel therapeutic
targets.
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